Roche Analyst Event at ASCO 2017

Agenda

The APHINITY study: 
Adjuvant Pertuzumab and Herceptin in Initial Therapy in patients with HER2-positive early breast cancer

- Jose Baselga, MD, PhD., Physician-in-Chief and Chief Medical Officer, Memorial Hospital, MSKCC

Highlights late stage portfolio

- Sandra Horning, M.D., Chief Medical Officer and Head Global Product Development

Highlights early development

- Ira Mellman, gRED: Ph.D., Vice President, Cancer Immunology, Genentech 
- William Pao, pRED: M.D., Ph.D., Global Head Oncology Discovery and Translational Area, Roche

Oncology business update

- Daniel O’Day, CEO Roche Pharmaceuticals 

Webcast Replay